Publications by authors named "James Cavet"

Claim this Profile
T
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Luciano Nicosia, Gary J Spencer, Nigel Brooks, Fabio M R Amaral, Naseer J Basma, James Cavet

Cancer Cell· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer and climate change: the environmental impact of cancer care.
Sarah Briggs, James Cavet, Carolynn Lamb, Sara Lightowlers

Lancet Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
Frits van Rhee, Jean-François Rossi, David Simpson, Alexander Fosså, Angela Dispenzieri, James Cavet

Br J Haematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma.
Salvatore Fiorenza, David Routledge, Jenny Collins, Michael Shipton, Simon Harrison, James Cavet

Bone Marrow Transplant· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Steve Schey, Sarah R Brown, Avie-Lee Tillotson, Kwee Yong, Cathy Williams, James Cavet

Br J Haematol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
Frits van Rhee, Margaret Rothman, Kai Fai Ho, Sarah Fleming, Raymond S Wong, James Cavet

Patient· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
Frits van Rhee, Raymond S Wong, Nikhil Munshi, Jean-Francois Rossi, Xiao-Yan Ke, James Cavet

Lancet Oncol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial.
Treen C M Morris, Cathy Williams, Sue Bell, Marie Fletcher, Alexander Szubert, James Cavet

Br J Haematol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, James Cavet

Lancet Oncol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Living with multiple myeloma: experiences of patients and their informal caregivers.
Alex Molassiotis, Barbara Wilson, Susan Blair, Tracy Howe, James Cavet

Support Care Cancer· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners.
Alex Molassiotis, Barbara Wilson, Susan Blair, Tracy Howe, James Cavet

Psychooncology· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
Karl S Peggs, Anna Sureda, Wendi Qian, Dolores Caballero, Ann Hunter, James Cavet

Br J Haematol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The fate of human Langerhans cells in hematopoietic stem cell transplantation.
Matthew P Collin, Derek N J Hart, Graham H Jackson, Gordon Cook, James Cavet

J Exp Med· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymorphisms of interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Hannah Cullup, Anne M Dickinson, James Cavet, Graham H Jackson, Peter G Middleton

Br J Haematol· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting outcome in hematological stem cell transplantation.
Anne M Dickinson, James Cavet, Hannah Cullup, Xiao N Wang, Mark Jarvis

Arch Immunol Ther Exp (Warsz)· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis